Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Antiapoptotic gene BAG-1 vector structure of RNA interference and endogenous targeted screening in colon cancer cell lines

Authors: Nian-feng Sun, Ai-ling Tian, Zhan-ao Liu, San-yuan Hu, An-bin Hu

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

The purposes of the present work were to construct the shRNA plasmids for BAG-1 gene of human and test the expression of mRNA and protein of BAG-1. Recombinant plasmids containing green fluorescent protein reporter genes are constructed using gene cloning methods. The shRNA plasmids for the BAG-1 gene are constructed by RNA interference technology. We applied fluorescent plasmid-transfected target cells in the cell transfection experiments and monitored the transfection rate of plasmids by observing the fluorescence amount. We transfected three synthesized shRNA in target screening cell and adopted RT-PCR and Western test to identify the difference of target gene transfection and translation level in cells. The specific shRNA plasmid for the BAG-1 gene was successfully recombined, and stably transfected colon cancer Lo Vo cell lines were obtained. The results present that the constructed shRNA plasmids significantly inhibited the expression of mRNA and protein of Lo Vo cell BAG-1, and can maintain the effect for a long term. pGPH1/GFP/Neo-BAG-1-homo-825 was screened as the optimum sequence of interference so as to lay a solid foundation to explore into the research on the BAG-1 gene and the biological behavior of colon cancer cells. It showed the remarkable advantage of RNAi in the generation of posttranscriptional gene silencing.
Literature
1.
go back to reference Lindgren M, Rosenthal-Aizman K, Saar K. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2006;71:416–25.PubMedCrossRef Lindgren M, Rosenthal-Aizman K, Saar K. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2006;71:416–25.PubMedCrossRef
2.
go back to reference Ortiz R, Melguizo C, Prados J, Alvarez PJ, Caba O, Rodriguez-Serrano F, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Patents on Anti-Cancer Drug Discovery. 2012;7:297–312. Ortiz R, Melguizo C, Prados J, Alvarez PJ, Caba O, Rodriguez-Serrano F, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Patents on Anti-Cancer Drug Discovery. 2012;7:297–312.
3.
go back to reference Leinonen HM, Ruotsalainen A-K, Määttä A-M, Laitinen HM, Kuosmanen SM. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Research. 2012;72:6227–35.PubMedCrossRef Leinonen HM, Ruotsalainen A-K, Määttä A-M, Laitinen HM, Kuosmanen SM. Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Research. 2012;72:6227–35.PubMedCrossRef
4.
go back to reference Van Laar RK. An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. British Journal of Cancer. 2010;103:1852–7.PubMedCentralPubMedCrossRef Van Laar RK. An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. British Journal of Cancer. 2010;103:1852–7.PubMedCentralPubMedCrossRef
5.
go back to reference de Gramont A, de Gramont A, Chibaudel B, Bachet J-B, Larsen AK, Tournigand C, et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Seminars in Oncology. 2011;38:521–32. de Gramont A, de Gramont A, Chibaudel B, Bachet J-B, Larsen AK, Tournigand C, et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Seminars in Oncology. 2011;38:521–32.
6.
go back to reference Dykxhoom DM, Liebennan J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005;56:401–23.CrossRef Dykxhoom DM, Liebennan J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005;56:401–23.CrossRef
7.
go back to reference Hua T, editor. The theory and apply of RNA interference. 1st ed. Beijing: Beijing Science and Technology Press; 2006. Hua T, editor. The theory and apply of RNA interference. 1st ed. Beijing: Beijing Science and Technology Press; 2006.
9.
go back to reference Maryla K, Bruce CT, Ahmed S, Stan K, John CR. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate. 2006;66:801–10.CrossRef Maryla K, Bruce CT, Ahmed S, Stan K, John CR. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate. 2006;66:801–10.CrossRef
10.
go back to reference Guo-bin W, Nian-feng S, Qing-xian H. Expression of the anti-apoptotic gene Bag-1 and Bcl-2 in the colorectal cancer and there interaction. Chin Eep Surg. 2005;22:227–8. Guo-bin W, Nian-feng S, Qing-xian H. Expression of the anti-apoptotic gene Bag-1 and Bcl-2 in the colorectal cancer and there interaction. Chin Eep Surg. 2005;22:227–8.
11.
go back to reference Nian-feng S, Jing-bo C, Guo-bin W. Expression and relation of the anti-apoptotic gene Bag-1 and Bcl-2 in the colon cancer. China Journal of Modern Medicine. 2007;17:769–72. Nian-feng S, Jing-bo C, Guo-bin W. Expression and relation of the anti-apoptotic gene Bag-1 and Bcl-2 in the colon cancer. China Journal of Modern Medicine. 2007;17:769–72.
12.
go back to reference Nian-feng S, Qing-yi M, Ai-ling T. Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. The American Journal of Surgery. 2010;200:341–5.CrossRef Nian-feng S, Qing-yi M, Ai-ling T. Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. The American Journal of Surgery. 2010;200:341–5.CrossRef
14.
go back to reference Yang JY, Cai ZQ, Du W, Li JC, Chen TX, Xu YH. The relationship between Bag-1 and gastric cancer clinicopathologic characteristic. The Chinese-German Journal of Clinical Oncology. 2011;10:459–61.CrossRef Yang JY, Cai ZQ, Du W, Li JC, Chen TX, Xu YH. The relationship between Bag-1 and gastric cancer clinicopathologic characteristic. The Chinese-German Journal of Clinical Oncology. 2011;10:459–61.CrossRef
15.
go back to reference Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathology & Oncology Research. 2012;18:929–37.CrossRef Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathology & Oncology Research. 2012;18:929–37.CrossRef
16.
go back to reference Clemo NK, Collard TJ, Southem SL. BAG-l is up-regulated in colorectal turnout progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 2008;29:849–57.PubMedCrossRef Clemo NK, Collard TJ, Southem SL. BAG-l is up-regulated in colorectal turnout progression and promotes colorectal tumour cell survival through increased NF-kappaB activity. Carcinogenesis. 2008;29:849–57.PubMedCrossRef
Metadata
Title
Antiapoptotic gene BAG-1 vector structure of RNA interference and endogenous targeted screening in colon cancer cell lines
Authors
Nian-feng Sun
Ai-ling Tian
Zhan-ao Liu
San-yuan Hu
An-bin Hu
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1140-1

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine